Hemopure: The Blood Substitute That Almost Was

In 2008, an FDA advisory panel sat down with a meta-analysis that pooled thirteen randomized trials of cell-free hemoglobin-based oxygen carriers — HBOCs, for short — and found that, as a class, these products increased the risk of myocardial infarction and death compared to controls. Within the year, the FDA had effectively frozen HBOC development in the United States. Almost two decades later, the freeze hasn’t really lifted. One of the products caught in it, Hemopure, has spent that entire time legally available in South Africa, used there since 2001 for acute surgical anemia, with no comparable reckoning.

That gap is the interesting part. Not whether Hemopure works — it does, in the narrow sense of carrying oxygen — but why a product can be standard of care in Johannesburg and investigational-only, accessible solely through expanded access protocols, in Boston.

The Pitch

Hemopure (HBOC-201) is purified, glutaraldehyde-polymerized bovine hemoglobin, suspended in a balanced electrolyte solution and packaged in a 250 mL bag. It solves, on paper, two of transfusion medicine’s oldest structural problems at once. First, compatibility: there’s no antigen to react to, so no type and screen, no crossmatch, no antibody workup — a feature that matters enormously for a patient with a complex alloantibody history, or a Jehovah’s Witness declining allogeneic blood, or a combat medic with no time and no lab. Second, supply: it’s shelf-stable at room temperature for years, not the 42 days we get out of refrigerated red cells. No cold chain, no expiration anxiety, no donor recruitment problem.

It is, in other words, exactly the product blood banking has wanted since the first synthetic oxygen carrier was proposed. Which is part of why its failure to gain US approval stings more than a typical drug rejection — this isn’t a marginal improvement on an existing therapy. It’s a different category of solution to a problem we still haven’t solved.

What the Meta-Analysis Actually Said

The 2008 Natanson analysis, published in JAMA, didn’t study Hemopure alone. It pooled data across five distinct molecules — HemAssist, PolyHeme, Hemolink, Hemopure, and Hemospan — spanning surgical, trauma, and stroke populations treated between 1980 and 2008. The conclusion was stark: roughly a 30% increase in risk of death and nearly a threefold increase in risk of myocardial infarction across the pooled trials. The FDA responded by putting HBOC research as a class on clinical hold, and pharmaceutical interest in the space mostly evaporated.

The proposed mechanism made biological sense and still does: free hemoglobin outside the protective confines of a red cell membrane scavenges nitric oxide, the molecule responsible for vasodilation. Scavenge enough of it and you get vasoconstriction, hypertension, and — plausibly — myocardial ischemia. This isn’t a manufacturing defect specific to one company. It’s closer to a property of cell-free hemoglobin itself, which is a much harder problem to engineer around.

The Harder Question

Here’s where I think the story gets genuinely uncomfortable, and where I have a hard time being charitable to the paper that started all of it. Natanson and colleagues pooled thirteen trials of five chemically distinct molecules — different polymerization strategies, different patient populations, different routes and doses, trauma and elective surgery and stroke trials run across nearly three decades — into a single composite risk estimate, and reported finding no significant statistical heterogeneity across that grab-bag. I find that more suspicious than reassuring. Getting a clean, homogeneous-looking signal out of five drugs that don’t share a structure, in populations that don’t share a baseline ischemic risk, is exactly the kind of result that should prompt a second look at the methodology rather than a press release. Several independent groups thought so too: JAMA ran six separate rebuttal letters in the same issue — from South African clinicians with the largest real-world experience with Hemopure, from the manufacturers, from trauma surgeons, from bioethicists — which is not a normal amount of pushback for one meta-analysis to generate. Natanson’s own paper acknowledged that the authors had struggled to obtain complete trial data directly from the companies, meaning the headline number was built partly on data the authors themselves described as incomplete. It also doesn’t help that the senior author, Sidney Wolfe of Public Citizen’s Health Research Group, had already petitioned the FDA over HBOC trial safety back in 2006 — two years before he co-authored the analysis that became the FDA’s rationale for freezing the entire class. None of that automatically makes the conclusion wrong. But a paper with this many independent critics, this much acknowledged missing data, and an author who’d staked out the answer in advance is not the kind of evidence I’d want sitting alone at the foundation of a two-decade regulatory freeze — and yet here we are, two decades later, and it still is.

And then there’s the South Africa and Russia question, which nobody seems eager to sit with for very long. If the safety signal were straightforwardly damning, you’d expect those approvals to have been revisited over twenty-plus years of real-world use. They haven’t been. Either the signal doesn’t replicate cleanly outside the specific trial populations that generated it, or post-marketing surveillance in those countries simply isn’t rigorous enough to have caught it — and I genuinely don’t know which of those is true. Both possibilities should make a transfusion medicine physician uneasy, just in different directions.

Meanwhile, expanded access use in the US has quietly continued for patients with life-threatening anemia and no other option — mostly Jehovah’s Witnesses and patients with antibody profiles that make compatible blood functionally unobtainable. Case series from these programs report real patients surviving severe anemia they likely wouldn’t have survived otherwise, alongside the same cardiovascular signal the trials raised. The regulatory caution and the individual patient calculus are not measuring the same thing, and I don’t think they’re supposed to converge. A population-level hold protecting against a class-wide signal can be correct and still be the wrong answer for the specific patient in front of you with no other option. Sitting with that tension honestly is harder than resolving it in either direction.

Where It Sits Now

Hemopure remains investigational in the US, available only through expanded access or clinical trial. HbO2 Therapeutics, the company that now holds the product after Biopure’s bankruptcy and a subsequent ownership chain, has kept it alive primarily through that compassionate-use pathway and continued approval in South Africa and Russia. The broader HBOC field never really recovered momentum after 2008; most of the other products named in the Natanson analysis are gone entirely. Hemopure is something closer to a survivor than a success — still infused, still studied in scattered case reports, still without a clear path to a US indication.

There’s a newer thread worth watching: small case literature on HBOC-201 for ischemic rescue in cardiology and vascular contexts, distinct from its original blood-substitute framing. Whether that becomes a real niche or stays anecdotal is an open question, and I’m not going to pretend I know which.

I don’t think this is a story with a villain. The FDA did what regulatory agencies are supposed to do when a meta-analysis raises a mortality signal across a drug class. But twenty years on, with the same product still quietly saving the occasional patient who has no other option, and still in routine use on two other continents, I find myself less sure than I’d like to be about whether the caution and the evidence are still pointing in the same direction — or whether we’re applying a 2008 verdict to a 2026 question.